dailypolitical.com
Neutralwww.dailypolitical.com ·
tela bio q1 earnings call highlights
TAX_DISEASE_HERNIALEADERTAX_FNCACT_PRESIDENTUSPEC_POLITICS_GENERAL1
Topic context
This topic has been covered 355361 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedTELA Bio (NASDAQ: TELA) reported modest Q1 revenue growth, driven by strong international sales. The launch of OviTex hernia repair product may support future revenue. No major supply chain or margin squeeze identified; impact is company-specific and weak.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Q1 2026 revenue $19.1M, +3% YoY
- International sales +41% YoY
- OviTex long-term resorbable reinforcement launched April 1
- Full-year guidance: at least 8% revenue growth over 2025
- Cash and equivalents $39.5M at quarter end
